Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Rider

Brain Injury Medicine Chattanooga, TN Medical Doctor

NPI 1699909481 CMS profile 121725

1 Siskin Plz Ste 101, Chattanooga, TN 37403

Open in the dashboard

General payments

$6,003

323 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Rider of Chattanooga, TN is reported in the CMS Open Payments database as having received $6,003 across 323 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $610 29
2024 General $631 35
2023 General $794 37
2022 General $916 48
2021 General $1,313 70
2020 General $869 51
2019 General $870 53

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Rider
  • Brain Injury Medicine median
  • Middle half of Brain Injury Medicine
  • National median

In program year 2025, general payments to Matthew Rider were reported at $610. Among 31 Brain Injury Medicine profiles paid that year, the median was $165 and the middle half received between $36 and $391.

Show as a table
Year Matthew Rider Brain Injury Medicine median Middle half National median
2019 $870 $110 $51–$240 $163
2020 $869 — — $114
2021 $1,313 $61 $22–$274 $132
2022 $916 $79 $26–$281 $149
2023 $794 $125 $49–$275 $160
2024 $631 $139 $75–$423 $164
2025 $610 $165 $36–$391 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ipsen Biopharmaceuticals, Inc $1,035 41 payments
  2. AbbVie, Inc. $591 35 payments
  3. Radius Health, Inc. $486 26 payments
  4. Avanir Pharmaceuticals, Inc. $414 24 payments
  5. Amgen Inc. $369 25 payments
  6. Janssen Pharmaceuticals, Inc $319 16 payments
  7. Collegium Pharmaceutical, Inc. $318 26 payments
  8. Flexion Therapeutics, Inc. $255 13 payments
  9. Allergan Inc. $233 16 payments
  10. Pfizer Inc. $217 12 payments
  11. Other $1,768 89 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,913 321 payments
  2. Education $91 2 payments
Products named General payments · program years 2019–2025
  1. DYSPORT $1,035 41 payments
  2. NUEDEXTA $414 24 payments
  3. EVENITY $369 25 payments
  4. Prolia $369 25 payments
  5. Tymlos $341 20 payments
  6. XARELTO $319 16 payments
  7. BOTOX Botox Therapeutic $317 20 payments
  8. XTAMPZA $274 23 payments
  9. Zilretta $255 13 payments
  10. BOTOX Hyperhydrosis $253 17 payments
  11. Other $2,831 152 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

30

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$302

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

50%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 15 $191
Baclofen Generic 15 $111

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$224,447

Of which drugs: $84,887

Medicare patients

412

Average age 77

Services billed

15,417

235 women, 177 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Ischemic heart disease 49%
Diabetes 47%
Depression 46%
Atrial fibrillation 43%
Chronic kidney disease 43%
Heart failure 41%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, abobotulinumtoxina, 5 units J0586 Office 15 11,060 $72,922

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DYSPORT
  • Ipsen Biopharmaceuticals, Inc $148
$148 — 11,060
BOTOX
  • AbbVie, Inc. $123
$123 — —
UBRELVY
  • AbbVie, Inc. $65
$65 — —
Tymlos
  • Radius Health, Inc. $60
$60 — —
QULIPTA
  • AbbVie, Inc. $34
$34 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

323 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Brain Injury Medicine in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record